Experimental leukemia combination proves toxic for older, frail patients
Credit: Queens University
About 32 percent of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the U.S. Food and Drug Administration to eventually pull the combination from the current study.
Released today at the 61st American Society of Hematology (ASH) Annual Meeting, the findings serve as both triumph and warning. The randomized, two-arm trial design allowed investigators to catch the toxicity signal early, just eight months after the first patient enrolled. The trial also illustrates the tension currently facing cancer researchers, as eligibility criteria for clinical trials are loosened and as evidence mounts that immunotherapies can cause serious side effects, particularly for patients, many of them older, managing other illnesses like diabetes.
“Our findings highlight special concerns that cancer physicians must consider as we enroll vulnerable populations,” said Annette Hay, M.D., a hematologist at Queen’s University in Canada who, along with Sarit Assouline, M.D., of McGill University Jewish General Hospital, co-leads this section of the leukemia trial. “We also see the importance of vigilance and close collaborations, including with the FDA, to ensure patient safety.”
The results stem from a trial run by the SWOG Cancer Research Network, a cancer clinical trials network funded by the National Cancer Institute (NCI) through the National Institutes of Health. Hay presented them in a poster session today in Orlando, Florida at the ASH Annual Meeting, the world’s largest conference devoted to blood diseases and blood cancers like lymphoma.
The study, S1612, is a unique collaboration between the Canadian Cancer Trials Group, where Hay and Assouline are members, and SWOG, the Alliance for Clinical Trials in Oncology, and the ECOG-ACRIN Cancer Research Group. All four groups are funded by NCI through their National Clinical Trials Network. S1612 launched in December 2018 to test treatments for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), a bone marrow disorder sometimes referred to as “pre-leukemia.”
Hay and the other investigators set out to minimize trial exclusions and allow older, less-fit adults to join. That’s because a majority of people who get AML and MDS are over the age of 60 when they’re diagnosed. However, these older adults have not been well-represented in trials because so many are barred from joining. To make trials more representative, and to make their results more generalizable, the American Society of Clinical Oncology and the Friends of Cancer Research called for more inclusive trial criteria in a series of articles published in 2017 in the Journal of Clinical Oncology. In 2018, the FDA and NCI both issued new enrollment guidelines for industry- and publicly-funded cancer trials, respectively, which allow patients with organ dysfunction or a past cancer diagnosis, among others, to be considered for enrollment.
There is an urgent need for new AML and MDS treatments. While the chemotherapy azacitidine is standard, few patients respond well to it. Hay and her collaborators wanted to add new drugs into the mix, including the immunotherapy nivolumab. Knowing that toxicities could result, especially in older, sicker patients, the team designed the trial to ensure maximum safety. Patients would be randomly selected to join one of three groups – patients who get azacitidine only, patients who get azacitidine and nivolumab, and patients who get azacitidine and midostaurin, a new type of targeted drug. By including a control group – patients only getting standard treatment – researchers could better spot problems with patients getting combinations.
In October 2018, after 78 patients enrolled, enrollment was suspended. At the time, researchers had found that four patients died due to side-effects from the azacitidine and nivolumab treatment, compared with one patient who died due to side effects from azacitidine only. While the number of early deaths didn’t reach statistical significance, they sent a possible toxicity signal to the study leadership. After a review of safety data, and consultation with the FDA, researchers tightened the eligibility requirements for patients who could get assigned to the azacitidine and nivolumab combination, and boosted side effect surveillance. In October 2019, the FDA removed the nivolumab combination from the trial.
In 2020, S1612 will reopen with the control group, the azacitidine and midostaurin group, and a new arm – in which patients will be treated with a combination of two chemotherapy agents – decitabine and cytarabine. In addition, the research team plans to continue to evaluate azacitidine and nivolumab in older, less fit adults, and are working to determine the appropriate population and refining the toxicity profile in order to move forward.
“There is a message here for us in cancer research,” Hay said. “As we broaden our trial eligibility criteria, we may be including patients who may not only have cancer but two, three, even five other diseases. So they may experience significant side effects from trial treatment, especially drugs that stimulate the immune system. It’s important to incorporate frailty screening tools in trial design.”
Funding for S1612 comes from the National Institutes of Health through the National Cancer Institute under grants CA180888, CA180819, CA180820, CA180821 and CA180863. Bristol Myers Squibb and Novartis Pharmaceuticals, Inc. provided nivolumab and midostaurin for the trial under their respective Cooperative Research and Development Agreement with NCI.
Along with Hay and Assouline, the S1612 study team includes Roland B. Walter, MD, PhD, of the University of Washington; Richard F. Little, MD, MPH, of the National Cancer Institute; Anna Moseley, MS, of the SWOG Statistics and Data Management Center at the Fred Hutchinson Cancer Research Center; Gail M. Sperling, MPH, CHES, of SWOG; Annie Im, MD, of University of Pittsburgh Cancer Institute; James M. Foran, MD, of Mayo Clinic, Jacksonville, Florida; Jerald Radich, MD, of Fred Hutchinson Cancer Research Center; Min Fang, MD, PhD, of Fred Hutchinson Cancer Research Center; Megan Othus, PhD, of the SWOG Statistics and Data Management Center at the Fred Hutchinson Cancer Research Center; Harry P. Erba, MD, PhD, Duke University; and Laura C. Michaelis, MD, of Medical College of Wisconsin.
SWOG Cancer Research Network is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.